Catabasis Pharma (CATB) Announces Presentation of Positive CAT-5571 Data in CF at NACFC

Catabasis Pharmaceuticals Presents Positive Data for CAT-5571, a Novel Activator of Autophagy, as a Potential Oral Treatment for Cystic Fibrosis at the 30th Annual North American Cystic Fibrosis Confe

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced positive preclinical data presented at the 30th Annual North American Cystic Fibrosis Conference (NACFC), which support CAT-5571 as a potential oral treatment for cystic fibrosis (CF) with potential effects on both the cystic fibrosis transmembrane conductance regulator (CFTR) and on bacterial... More